Press Releases Mesoblast Limited

Equities

MSB

AU000000MSB8

Delayed Australian S.E. Other stock markets 09:10:12 2024-06-02 pm EDT			5-day change	1st Jan Change
1.13 ^AUD	+1.80%		-2.16%	+264.52%

May. 01	Mesoblast Limited Announces Board and Committee Changes	CI
Apr. 01	ADRs End Higher; Connect Biopharma Climbs 26%	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mesoblast Corporate Presentation at Investor Conference	08:24pm	AQ
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024	Apr. 29	AQ
Reddit Inc. (NYSE: RDDT) Surges, Uncovering Undervalued Opportunities: DYAI, INBS, MESO, VTAK	Mar. 28	AQ
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)	Mar. 25	AQ
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer	Mar. 13	AQ
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)	Mar. 10	AQ
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023	Feb. 28	AQ
Mesoblast Financial Results and Corporate Update Webcast	Feb. 26	AQ
MESOBLAST - UNITED STATES FOOD & DRUG ADMINISTRATION GRANTS MESOBLAST ORPHAN-DRUG DESIGNATION FOR REVASCOR IN CHILDREN WITH CONGENITAL HEART DISEASE	Feb. 15	AQ
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease	Feb. 14	AQ
MESOBLAST LIMITED - APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED DECEMBER 31, 2023	Jan. 31	AQ
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023	Jan. 30	AQ
MESOBLAST - UNITED STATES FOOD AND DRUG ADMINISTRATION GRANTS MESOBLAST RARE PEDIATRIC DISEASE DESIGNATION FOR REVASCOR IN CHILDREN WITH CONGENITAL HEART DISEASE	Jan. 19	AQ
United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease	Jan. 18	AQ
Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease	Nov. 26	AQ
Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD	Nov. 21	AQ
MESOBLAST - APPENDIX 4C QUARTERLY ACTIVITY REPORT FOR QUARTER ENDED SEPTEMBER 30, 2023	23-10-31	AQ
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023	23-10-30	AQ
Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee	23-09-26	AQ
Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval	23-09-21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Mesoblast Limited

Equities

MSB

AU000000MSB8

Press Releases

Filters